HighTide Therapeutics
Susan Gamble, PhD, RAC (US) is an accomplished regulatory affairs professional with extensive experience in leading FDA regulatory activities across various companies. Currently serving as Senior Director of Regulatory Affairs at HighTide Therapeutics, Gamble manages regulatory strategy and operations for both US and Chinese teams. Previous roles include Senior Director at CROMSOURCE, where regulatory and consulting services were provided to sponsors, and Assistant Director at Chiesi Pharmaceuticals, contributing to a 505(b)(2) NDA approval for an antibiotic. Gamble has a strong background in clinical research and has held positions at Supernus Pharmaceuticals, Shire, Sucampo Pharmaceuticals, and Cato Research, where numerous regulatory submissions and clinical development strategies were developed and executed. Gamble has also contributed to academia as Adjunct Faculty at Johns Hopkins University and holds a PhD in Genetics from The George Washington University, along with a Bachelor's degree in Chemistry from Mount Holyoke College.
This person is not in any teams
This person is not in any offices
HighTide Therapeutics
1 followers
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.